Sean Flynn Buys Shares of VCEL $VCEL

Editorial illustration for Vericel Corporation (VCEL)

Key Points

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Sean Flynn, Chief Legal Officer at Vericel Corporation ($VCEL), bought 15,000 shares at an average price of $16.25, for a total transaction of $243,750. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Vericel Corporation Stock Down 1.2%

Shares of Vericel Corporation ($VCEL) traded around $40.47 on Tuesday, down 1.2% for the day.

Last price$40.47
Market cap$2.04B
P/E ratio83.13
Forward P/E47.16
Beta1.07
52-week low$28.95
52-week high$49.32
50-day MA$44.77
200-day MA$38.15
Current ratio5.04
Quick ratio4.53
Debt-to-equity0.25

Vericel Corporation Earnings

EPS (ttm)$0.48
Revenue (ttm)$306.30M
Revenue growth22.50%
Net margin7.91%
Return on equity7.16%
Next earningsNov 5, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$60.57
High target$72
Low target$55
Analysts covering7

About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

ExchangeNasdaqGM
SectorHealthcare
IndustryBiotechnology
HeadquartersBurlington, MA
CEOMr. Dominick C. Colangelo Esq.
Employees398

Get Vericel Corporation alerts

New 13F filings, insider trades, and analyst moves on $VCEL, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.